Translational Research Group on Pediatric Solid Tumors
Oncology Area
Genomic heterogeneity in neuroblastoma (NB), especially in MYCN amplification
Xenotransplant models of NB
Importance of extracellular matrix and vascularization in NB
Morphological and molecular analysis of neuroblastic and malignant infantile skeletal tumors
Coordinator
Dr. Samuel Navarro Fos
samuel.navarro@uv.es; navarro@uv.es
Coordinator
Dr. Rosa Noguera Salvá
rosa.noguera@uv.es
STAFF
Collaborating Researchers
Amparo Compañ QuilisMara StoksMarta Gómez Rebolledo
Nurse
Technicians
Administrative assistant
Publications
Digital image analysis workflows for evaluation of cell behavior and tumor microenvironment to aid therapeutic assessment in high-risk neuroblastoma. Stoks M, Vieco-Marti I, Noguera I, Sanchez-Sanchez M, Burgos-Panadero R, Navarro S, Noguera R. Computers in Biology and Medicine. 2023 Aug 14;164:107364. doi: 10.1016/j.compbiomed.2023.107364. PMID: 37598482
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial. Alexander S, Auperin A, Bomken S, Csoka M, Kazanowska B, Chiang A, Andres M, Uyttebroeck A, Burke G, Zsiros J, Pillon M, Bollard C, Mussolin L, Verdu-Amoros J, Neven B, Barkauskas D, Wheatley K, Patte C, Gross T, Minard-Colin V. Lancet. Haematology. 2023 Jun;10(6):e445-e457. doi: 10.1016/S2352-3026(23)00062-5. PMID: 37094596
Extra-meningeal solitary fibrous tumor: an evolving entity with chameleonic morphological diversity, a hallmark molecular alteration and unresolved issues in risk stratification assessment. Machado I, Giner F, Cruz J, Lavernia J, Marhuenda-Fluixa A, Claramunt R, Lopez-Guerrero J, Navarro S, Ferrandez A, Blazquez Bujeda A, Ruiz-Sauri A, Llombart-Bosch A. Histology and Histopathology. 2023 Oct;38(10):1079-1097. doi: 10.14670/HH-18-608. PMID: 36975173
Evaluation of alternative risk stratification systems in a large series of solitary fibrous tumors with molecular findings and Ki-67 Index Data: do they improve risk assessment?. Machado I, Bujeda A, Giner F, Morales M, Cruz J, Lavernia J, Navarro S, Ferrandez A, Ruiz-Sauri A, Llombart-Bosch A. International Journal of Molecular Sciences. 2022 Dec 27;24(1):439. doi: 10.3390/ijms24010439. PMID: 36613891
Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness. Sonzini G, Granados-Aparici S, Sanegre S, Diaz-Lagares A, Diaz-Martin J, de Andrea C, Eritja N, Bao-Caamano A, Costa-Fraga N, Garcia-Ros D, Salguero-Aranda C, Davidson B, Lopez-Lopez R, Melero I, Navarro S, Ramon Y Cajal S, de Alava E, Matias-Guiu X, Noguera R. Frontiers in Cell and Developmental Biology. 2022 Nov 18;10:1052098. doi: 10.3389/fcell.2022.1052098. PMID: 36467415
The complexity of cancer immunotherapy illustrated through skin tumors. Vieco-Marti I, Lopez-Carrasco A, de la Cruz-Merino L, Noguera R, Alvaro Naranjo T. International Journal of Biological Markers. 2022 Jun;37(2):113-122. doi: 10.1177/03936155221088884. PMID: 35473449
Frequency and prognostic impact of alk amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Bellini A, Potschger U, Bernard V, Lapouble E, Baulande S, Ambros PF, Auger N, Beiske K, Bernkopf M, Betts DR, Bhalshankar J, Bown N, de Preter K, Clement N, Combaret V, Font de Mora J, George SL, Jimenez I, Jeison M, Marques B, Martinsson T, Mazzocco K, Morini M, Muhlethaler-Mottet A, Noguera R, Pierron G, Rossing M, Taschner-Mandl S, Van Roy N, Vicha A, Chesler L, Balwierz W, Castel V, Elliott M, Kogner P, Laureys G, Luksch R, Malis J, Popovic-Beck M, Ash S, Delattre O, Valteau-Couanet D, Tweddle DA, Ladenstein R, Schleiermacher G. Journal of Clinical Oncology. 2021 Oct 20;39(30):3377-3390. doi: 10.1200/JCO.21.00086. PMID: 34115544
Immunometabolism modulation in therapy. Monferrer E, Sanegre S, Vieco-Marti I, Lopez-Carrasco A, Farinas F, Villatoro A, Abanades S, Manes S, de la Cruz-merino L, Noguera R, Naranjo T. Biomedicines. 2021 Jul 9;9(7):798. doi: 10.3390/biomedicines9070798. PMID: 34356862
Integrated CGH/WES analyses advance understanding of aggressive neuroblastoma evolution: a case study. Corallo D, Zanon C, Pantile M, Tonini G, Zin A, Francescato S, Rossi B, Trevisson E, Pinato C, Monferrer E, Noguera R, Alino S, Herrero M, Biffi A, Viscardi E, Aveic S. Cells. 2021 Oct 9;10(10):2695. doi: 10.3390/cells10102695. PMID: 34685674
Projects
Title: INtegrative GENomic, digital Imaging and clinical information towars Precision Oncology Optimization – INGENIO
Funding body: Ministerio de Ciencia e Innovación
Principal Investigator: Luis Paz-Ares Rodríguez
Duration: 2021 – 2024
Total budget: 3.780.700 €
Title: Implantación de una plataforma de análisis genético de última generación para la investigación en genética biomédica
Funding body: Conselleria de Educación, Investigación, Cultura y Deporte
Principal Investigator: Rosa Noguera Salvá
Duration: 2021 – 2027
Total budget: 365.143 €
Title: Espacio intercelular: Bioimagen microscópica, Fase II
Funding body: Fundación Neuroblastoma
Principal Investigator: Rosa Noguera Salvá
Duration: 2021 – 2024
Total budget: 20.000 €
Title: Neuroblastoma: estrategias mecanoterapéuticas basadas en modelos 3D y tumores derivados de pacientes con microambiente rico en vitronectina
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Rosa Noguera Salvá
Duration: 2021 – 2023
Total budget: 232.320 €
Title: Cancer Stroma Assessment through Digital Pathology
Funding body: CIBERONC
Principal Investigator: Núria Malats
Duration: 2021 – 2023
Total budget: 90.000 €
Title: Espacio intercelular: Bioimagen microscópica, Fase II
Funding body: Fundación Neuroblastoma
Principal Investigator: Rosa Noguera Salvá
Duration: 2019 – 2021
Total budget: 90.000 €
Title: Identificación y validación de nuevas terapias, modelos preclínicos y marcadores de respuesta
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Rosa Noguera Salvá
Duration: 2018 – 2020
Total budget: 123.420 €
Title: CIBER Oncología (CIBERONC)
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Rosa Noguera Salvá
Duration: 2017 –
Total budget: 360.000 €
+ Info
Doctoral candidate: Martínez Lapiedra, Carmen
Director(s): Navarro Fos, Samuel; Machado Puerto, Isidro
Date of the defense: 19/05/2023
University: University de ValenciaTitle: Transmisión de señales mecánicas en células indiferenciadas neuroblásticas. Estudios biológicos y preclínicos en modelos in vitro 3D
Doctoral candidate: Monferrer Garzarán, Ezequiel
Director(s): Noguera Salvá, Rosa
Date of the defense: 03/04/2023
University: Universitat de València
Title: Búsqueda de dianas terapéuticas en los puntos de contacto de la célula tumoral con su matriz extracelular en tumores neuroblásticos
Doctoral candidate: Burgos Panadero, Rebeca
Director(s): Noguera Salvá, Rosa; Navarro Fos, Samuel
Date of the defense: 31/07/2020
University: Universitat de València